Neoleukin Pauses Development Of NL-201, Cuts 40% Of Employee Strength
Neoleukin Therapeutics Inc (NASDAQ:NLTX) announced discontinuing the development of NL-201 for strategic reasons. Preliminary monotherapy data from the Phase 1 study…
Intellia Therapeutics To Rally Around 143%? Plus Stifel Cuts PT On This Stock By 94%
Chardan Capital boosted the price target on Intellia Therapeutics, Inc. (NASDAQ: NTLA) from $121 to $129. Intellia Therapeutics shares fell 3% to close at $53.30 on Monday.
Guggenheim Downgrades Neoleukin Therapeutics to Neutral
Guggenheim analyst Michael Schmidt downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 528 companies set new 52-week lows.
B of A Securities Downgrades Neoleukin Therapeutics to Underperform, Announces $1 Price Target
B of A Securities analyst Greg Harrison downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Underperform and announces $1 price target.
HC Wainwright Cuts Price Target On This Stock By 73%, Also Check Out Other Major PT Changes Here
Susquehanna cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $195. Susquehanna analyst Shyam Patil maintained the stock with a Positive rating. Baidu shares rose 0.7% to $139.38 in pre-market trading.